Experienced in Infantile Neutropenia

Dr. Scott C. Borinstein

Pediatric Hematology Oncology

2200 Childrens Way,

Nashville, TN

Offers Telehealth

Experienced in Infantile Neutropenia

2200 Childrens Way,

Nashville, TN

OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Scott Borinstein is a Pediatric Hematologist Oncology provider in Nashville, Tennessee. Dr. Borinstein is rated as an Experienced provider by MediFind in the treatment of Infantile Neutropenia. His top areas of expertise are Osteosarcoma, Ewing Sarcoma, Adult Soft Tissue Sarcoma, Rhabdomyosarcoma, and Bone Marrow Aspiration.

His clinical research consists of co-authoring 62 peer reviewed articles and participating in 38 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of Infantile Neutropenia.

Specialties

Pediatric Hematology Oncology

Licenses

Pediatric Hematology-Oncology in WA

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance

Find your insuranceClose

Accepted insurance plans:

Aetna

Alliant Health

Anthem

Blue Cross Blue Shield

Cigna

Highmark

Humana

HMO
INDEMNITY
POS
PPO

Managed Medicaid

OTHER MANAGED MEDICAID

Oscar

UnitedHealthcare

Wellcare

EPO
HMO
INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE PDP
MEDICARE SNP
MEDICARE-MEDICAID PLAN
OTHER MEDICARE
OTHER MEDICARE PART D

View 6 Less Insurance Carriers -

Locations

2200 Childrens Way, Nashville, TN 37232

Call: 615-936-2000

Additional Areas of Focus

Dr. Borinstein has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

37 Clinical Trials

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Tipifarnib in Patients With Tumors Harboring HRAS Genomic Alterations

Enrollment Status: Active_not_recruiting

Publish Date: December 04, 2025

Intervention Type: Drug

Study Drug: Tipifarnib

Study Phase: Phase 2

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-292 in Patients With Tumors Harboring RET Gene Alterations

Enrollment Status: Active_not_recruiting

Publish Date: December 04, 2025

Intervention Type: Procedure, Drug

Study Drug: Selpercatinib

Study Phase: Phase 2

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-101 (Larotrectinib) in Patients With Tumors Harboring Actionable NTRK Fusions

Enrollment Status: Active_not_recruiting

Publish Date: December 03, 2025

Intervention Type: Procedure, Drug

Study Drugs: Larotrectinib, Larotrectinib Sulfate

Study Phase: Phase 2

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of BVD-523FB (Ulixertinib) in Patients With Tumors Harboring Activating MAPK Pathway Mutations

Enrollment Status: Active_not_recruiting

Publish Date: December 03, 2025

Intervention Type: Other, Drug

Study Drug: Ulixertinib

Study Phase: Phase 2

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Erdafitinib in Patients With Tumors Harboring FGFR1/2/3/4 Alterations

Enrollment Status: Active_not_recruiting

Publish Date: December 02, 2025

Intervention Type: Procedure, Other, Drug

Study Drug: Erdafitinib

Study Phase: Phase 2

A Safety, Pharmacokinetic and Efficacy Study of a y-Secretase Inhibitor, Nirogacestat (PF-03084014), in Children and Adolescents With Progressive, Surgically Unresectable Desmoid Tumors

Enrollment Status: Active_not_recruiting

Publish Date: December 02, 2025

Intervention Type: Other, Procedure, Drug

Study Drug: Nirogacestat

Study Phase: Phase 2

Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754)

Enrollment Status: Active_not_recruiting

Publish Date: December 01, 2025

Intervention Type: Drug, Radiation, Procedure

Study Drugs: Doxorubicin, Ifosfamide, Pazopanib

Study Phase: Phase 2/Phase 3

Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma

Enrollment Status: Active_not_recruiting

Publish Date: December 01, 2025

Intervention Type: Drug, Procedure, Biological, Radiation

Study Drugs: Cyclophosphamide, Doxorubicin, Doxorubicin Hydrochloride, Etoposide, Etoposide Phosphate, Ganitumab, Ifosfamide, Vincristine, Vincristine Sulfate

Study Phase: Phase 3

Phase II Study of Nab-Paclitaxel in Combination With Gemcitabine for Treatment of Recurrent/Refractory Sarcoma in Teenagers and Young Adults

Enrollment Status: Active_not_recruiting

Publish Date: December 01, 2025

Intervention Type: Drug

Study Drugs: Nab-Paclitaxel, Gemcitabine

Study Phase: Phase 2

A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)

Enrollment Status: Active_not_recruiting

Publish Date: December 01, 2025

Intervention Type: Radiation, Drug, Biological, Other

Study Drugs: Cyclophosphamide, Dactinomycin, Irinotecan hydrochloride, Temsirolimus, Vincristine sulfate, Vinorelbine

Study Phase: Phase 3

Evolutionary Inspired Therapy for Newly Diagnosed, Metastatic, Fusion Positive Rhabdomyosarcoma

Enrollment Status: Active_not_recruiting

Publish Date: November 26, 2025

Intervention Type: Drug

Study Drugs: Vincristine, Cyclophosphamide, Vinorelbine, Actinomycin D, Cyclophosphamide pill

Study Phase: Phase 2

Treatment of Children With All Stages of Hepatoblastoma With Temsirolimus (NSC#683864) Added to High Risk Stratum Treatment

Enrollment Status: Active_not_recruiting

Publish Date: November 25, 2025

Intervention Type: Drug, Other, Procedure

Study Drugs: Cisplatin, Dexrazoxane, Doxorubicin Hydrochloride, Fluorouracil, Irinotecan Hydrochloride, Temsirolimus, Vincristine Sulfate

Study Phase: Phase 3

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol

Enrollment Status: Active_not_recruiting

Publish Date: November 17, 2025

Intervention Type: Procedure, Drug, Other

Study Drugs: Ensartinib, Erdafitinib, Larotrectinib, Olaparib, Palbociclib, Samotolisib, Selpercatinib, Selumetinib Sulfate, Tazemetostat, Tipifarnib, Ulixertinib, Vemurafenib

Study Phase: Phase 2

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of AG-120 (Ivosidenib) in Patients With Tumors Harboring IDH1 Mutations

Enrollment Status: Active_not_recruiting

Publish Date: November 17, 2025

Intervention Type: Drug

Study Drug: Ivosidenib

Study Phase: Phase 2

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Ensartinib in Patients With Tumors Harboring ALK or ROS1 Genomic Alterations

Enrollment Status: Active_not_recruiting

Publish Date: November 17, 2025

Intervention Type: Procedure, Other, Drug

Study Drug: Ensartinib

Study Phase: Phase 2

A Phase Ib/II Study to Evaluate the Safety, Feasibility and Efficacy of Nivolumab or Nivolumab in Combination With Azacitidine in Patients With Recurrent, Resectable Osteosarcoma

Enrollment Status: Active_not_recruiting

Publish Date: October 31, 2025

Intervention Type: Drug, Procedure

Study Drugs: Nivolumab, Azacitidine

Study Phase: Phase 1

A Phase 2 Study of DS-8201a (NSC# 807708) in Adolescents, or Young Adults With Recurrent HER2+ Osteosarcoma

Enrollment Status: Suspended

Publish Date: October 31, 2025

Intervention Type: Biological, Procedure

Study Drug: Trastuzumab Deruxtecan

Study Phase: Phase 2

A Phase 2 Study of the MEK Inhibitor Trametinib (NSC# 763093) in Children With Relapsed or Refractory Juvenile Myelomonocytic Leukemia

Enrollment Status: Active_not_recruiting

Publish Date: October 29, 2025

Intervention Type: Procedure, Drug

Study Drug: Trametinib

Study Phase: Phase 2

International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones

Enrollment Status: Active_not_recruiting

Publish Date: October 27, 2025

Intervention Type: Drug, Procedure, Other, Biological

Study Drugs: Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Dexrazoxane Hydrochloride, Doxorubicin, Etoposide, Filgrastim, Ifosfamide, Imatinib Mesylate, Leucovorin Calcium, Mercaptopurine, Methotrexate, Methylprednisolone, Pegaspargase, Prednisolone, Hydrocortisone, Thioguanine, Vincristine Sulfate

Study Phase: Phase 3

A Phase 2 Randomized Study of Irinotecan/Temozolomide/Dinutuximab With or Without Eflornithine (DFMO) in Children With Relapsed, Refractory or Progressive Neuroblastoma

Enrollment Status: Active_not_recruiting

Publish Date: October 27, 2025

Intervention Type: Drug, Biological

Study Drugs: Dinutuximab, Eflornithine Hydrochloride, Irinotecan Hydrochloride, Sargramostim, Temozolomide

Study Phase: Phase 2

A Phase I/II Study of Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemia, Study ITCC-054/COG-AAML1921

Enrollment Status: Active_not_recruiting

Publish Date: September 18, 2025

Intervention Type: Drug

Study Drug: Bosutinib

Study Phase: Phase 1/Phase 2

Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)

Enrollment Status: Active_not_recruiting

Publish Date: September 02, 2025

Intervention Type: Drug, Other, Procedure

Study Drugs: Carboplatin, Cisplatin, Doxorubicin, Etoposide, Fluorouracil, Gemcitabine, Irinotecan, Oxaliplatin, Sorafenib, Vincristine Sulfate

Study Phase: Phase 3

Renal Tumors Classification, Biology, and Banking Study

Enrollment Status: Active_not_recruiting

Publish Date: March 25, 2025

Intervention Type: Other

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Selumetinib (AZD6244 Hydrogen Sulfate) in Patients With Tumors Harboring Activating MAPK Pathway Mutations

Enrollment Status: Completed

Publish Date: February 05, 2025

Intervention Type: Drug, Other

Study Drugs: Selumetinib, Selumetinib Sulfate

Study Phase: Phase 2

NCI-COG Pediatric MATCH (Molecular Analysis For Therapy Choice)- Phase 2 Subprotocol of LY3023414 in Patients With Solid Tumors

Enrollment Status: Completed

Publish Date: January 27, 2025

Intervention Type: Procedure, Drug

Study Drug: Samotolisib

Study Phase: Phase 2

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Vemurafenib in Patients With Tumors Harboring BRAF V600 Mutations

Enrollment Status: Completed

Publish Date: January 27, 2025

Intervention Type: Other, Drug

Study Drug: Vemurafenib

Study Phase: Phase 2

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Tazemetostat in Patients With Tumors Harboring Alterations in EZH2 or Members of the SWI/SNF Complex

Enrollment Status: Completed

Publish Date: January 27, 2025

Intervention Type: Drug

Study Drug: Tazemetostat

Study Phase: Phase 2

A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) As First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors

Enrollment Status: Active_not_recruiting

Publish Date: January 13, 2025

Intervention Type: Drug, Procedure

Study Drugs: Paclitaxel, Ifosfamide, Cisplatin, Pegylated G-CSF, G-CSF, Carboplatin, Etoposide Phosphate

Study Phase: Phase 3

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- A Phase 2 Subprotocol of Olaparib in Patients With Tumors Harboring Defects in DNA Damage Repair Genes

Enrollment Status: Completed

Publish Date: December 11, 2024

Intervention Type: Drug

Study Drug: Olaparib

Study Phase: Phase 2

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Palbociclib in Patients With Tumors Harboring Activating Alterations in Cell Cycle Genes

Enrollment Status: Completed

Publish Date: November 01, 2024

Intervention Type: Other, Drug

Study Drug: Palbociclib

Study Phase: Phase 2

Effects of Modern Chemotherapy Regimens on Spermatogenesis and Steroidogenesis in Adolescent and Young Adult (AYA) Survivors of Osteosarcoma

Enrollment Status: Completed

Publish Date: August 26, 2024

Intervention Type: Procedure, Other

A COG Study for Collecting and Banking Ewing Sarcoma Specimens

Enrollment Status: Completed

Publish Date: October 03, 2023

Intervention Type: Other

A COG Soft Tissue Sarcoma Diagnosis, Biology and Banking Protocol

Enrollment Status: Completed

Publish Date: October 03, 2023

Intervention Type: Other

A Phase 2 Study of GPNMB-Targeted Antibody-Drug Conjugate, CDX-011 (Glembatumumab Vedotin, CR011-vcMMAE; NSC# 763737), in Recurrent or Refractory Osteosarcoma

Enrollment Status: Completed

Publish Date: January 18, 2022

Intervention Type: Other, Drug

Study Drug: Glembatumumab Vedotin

Study Phase: Phase 2

A Phase 1, Open-Label, Dose-Escalation Study of Olaratumab as a Single Agent and in Combination With Doxorubicin, Vincristine/Irinotecan, or High-Dose Ifosfamide in Pediatric Patients With Relapsed or Refractory Solid Tumors

Enrollment Status: Completed

Publish Date: May 20, 2020

Intervention Type: Drug

Study Phase: Phase 1

A Phase 1b Trial to Assess the Modulation of Biological Markers in Patients With Potentially Resectable Soft Tissue Sarcoma Treated With Olaratumab Monotherapy Followed by Olaratumab Plus Doxorubicin Combination Therapy

Enrollment Status: Completed

Publish Date: August 12, 2019

Intervention Type: Drug, Radiation

Study Phase: Phase 1

A Children's Oncology Group Protocol for Collecting and Banking Pediatric Research Specimens Including Rare Pediatric Tumors

Enrollment Status: Completed

Publish Date: July 19, 2018

Intervention Type: Other

View 36 Less Clinical Trials

62 Total Publications

Desmoid tumor control with liposomal doxorubicin: a dual-center retrospective analysis.

Journal: Expert review of anticancer therapy

Published: August 19, 2025

View All 62 Publications

Similar Doctors

Elite in Infantile Neutropenia

Dr. Adam J. Esbenshade

Pediatric Hematology Oncology

Elite in Infantile Neutropenia

Dr. Adam J. Esbenshade

Pediatric Hematology Oncology

Vanderbilt University Medical Center

1301 22nd Ave S,

Nashville, TN

(0.2 miles away)

615-322-3000

Languages Spoken:

English

See accepted insurances

Offers Telehealth

Adam Esbenshade is a Pediatric Hematologist Oncology provider in Nashville, Tennessee. Dr. Esbenshade is rated as a Distinguished provider by MediFind in the treatment of Infantile Neutropenia. His top areas of expertise are Infantile Neutropenia, Febrile Neutropenia, Acute Lymphoblastic Leukemia (ALL), Multisystem Inflammatory Syndrome in Children (MIS-C), and Bone Marrow Transplant.

Distinguished in Infantile Neutropenia

Dr. James A. Connelly

Pediatric Hematology Oncology

Distinguished in Infantile Neutropenia

Dr. James A. Connelly

Pediatric Hematology Oncology

Vanderbilt University Medical Center

1301 Medical Ctr Dr,

Nashville, TN

(0.2 miles away)

615-322-5000

Languages Spoken:

English

See accepted insurances

Offers Telehealth

James Connelly is a Pediatric Hematologist Oncology provider in Nashville, Tennessee. Dr. Connelly is rated as a Distinguished provider by MediFind in the treatment of Infantile Neutropenia. His top areas of expertise are Infantile Neutropenia, Severe Combined Immunodeficiency (SCID), Graft Versus Host Disease (GvHD), Bone Marrow Transplant, and Splenectomy.

Distinguished in Infantile Neutropenia

Dr. Debra L. Friedman

Pediatric Hematology Oncology

Distinguished in Infantile Neutropenia

Dr. Debra L. Friedman

Pediatric Hematology Oncology

2200 Childrens Way,

Nashville, TN

(0.1 miles away)

615-936-2000

Languages Spoken:

English

See accepted insurances

Offers Telehealth

Debra Friedman is a Pediatric Hematologist Oncology provider in Nashville, Tennessee. Dr. Friedman is rated as a Distinguished provider by MediFind in the treatment of Infantile Neutropenia. Her top areas of expertise are Hodgkin Lymphoma, Retinoblastoma, Infantile Neutropenia, and Febrile Neutropenia.

VIEW MORE INFANTILE NEUTROPENIA DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Borinstein's expertise for a condition

ConditionClose